Alamar Biosciences said it will use its Nulisa platform to collaborate with GlaxoSmithKline to study circulating protein characteristics and disease progression. Alamar said the study will examine the relationship between circulating protein characteristics and disease progression, biological subtypes, and treatment response, covering respiratory, liver, kidney, neurological, and autoimmune conditions.

Zhitongcaijing · 6d ago
Alamar Biosciences said it will use its Nulisa platform to collaborate with GlaxoSmithKline to study circulating protein characteristics and disease progression. Alamar said the study will examine the relationship between circulating protein characteristics and disease progression, biological subtypes, and treatment response, covering respiratory, liver, kidney, neurological, and autoimmune conditions.